Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea; Institute of Tissue Regeneration, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea; Department of Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.
Metabolism. 2024 Oct;159:155982. doi: 10.1016/j.metabol.2024.155982. Epub 2024 Jul 30.
Receptor-interacting protein kinase (RIPK)3 is an essential molecule for necroptosis and its role in kidney fibrosis has been investigated using various kidney injury models. However, the relevance and the underlying mechanisms of RIPK3 to podocyte injury in albuminuric diabetic kidney disease (DKD) remain unclear. Here, we investigated the role of RIPK3 in glomerular injury of DKD.
We analyzed RIPK3 expression levels in the kidneys of patients with biopsy-proven DKD and animal models of DKD. Additionally, to confirm the clinical significance of circulating RIPK3, RIPK3 was measured by ELISA in plasma obtained from a prospective observational cohort of patients with type 2 diabetes, and estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), which are indicators of renal function, were followed up during the observation period. To investigate the role of RIPK3 in glomerular damage in DKD, we induced a DKD model using a high-fat diet in Ripk3 knockout and wild-type mice. To assess whether mitochondrial dysfunction and albuminuria in DKD take a Ripk3-dependent pathway, we used single-cell RNA sequencing of kidney cortex and immortalized podocytes treated with high glucose or overexpressing RIPK3.
RIPK3 expression was increased in podocytes of diabetic glomeruli with increased albuminuria and decreased podocyte numbers. Plasma RIPK3 levels were significantly elevated in albuminuric diabetic patients than in non-diabetic controls (p = 0.002) and non-albuminuric diabetic patients (p = 0.046). The participants in the highest tertile of plasma RIPK3 had a higher incidence of renal progression (hazard ratio [HR] 2.29 [1.05-4.98]) and incident chronic kidney disease (HR 4.08 [1.10-15.13]). Ripk3 knockout improved albuminuria, podocyte loss, and renal ultrastructure in DKD mice. Increased mitochondrial fragmentation, upregulated mitochondrial fission-related proteins such as phosphoglycerate mutase family member 5 (PGAM5) and dynamin-related protein 1 (Drp1), and mitochondrial ROS were decreased in podocytes of Ripk3 knockout DKD mice. In cultured podocytes, RIPK3 inhibition attenuated mitochondrial fission and mitochondrial dysfunction by decreasing p-mixed lineage kinase domain-like protein (MLKL), PGAM5, and p-Drp1 S616 and mitochondrial translocation of Drp1.
The study demonstrates that RIPK3 reflects deterioration of renal function of DKD. In addition, RIPK3 induces diabetic podocytopathy by regulating mitochondrial fission via PGAM5-Drp1 signaling through MLKL. Inhibition of RIPK3 might be a promising therapeutic option for treating DKD.
受体相互作用蛋白激酶(RIPK)3 是细胞程序性坏死(necroptosis)的必需分子,其在肾脏纤维化中的作用已在各种肾脏损伤模型中得到研究。然而,RIPK3 与白蛋白尿性糖尿病肾病(DKD)中足细胞损伤的相关性及其潜在机制仍不清楚。本研究旨在探讨 RIPK3 在 DKD 肾小球损伤中的作用。
我们分析了经活检证实的 DKD 患者和 DKD 动物模型肾脏中 RIPK3 的表达水平。此外,为了确认循环 RIPK3 的临床意义,我们通过 ELISA 法检测了来自前瞻性观察性队列的 2 型糖尿病患者的血浆 RIPK3 水平,同时在观察期间对估计肾小球滤过率(eGFR)和尿白蛋白/肌酐比值(UACR)进行了随访,这些指标均反映了肾功能的情况。为了研究 RIPK3 在 DKD 肾小球损伤中的作用,我们使用高脂肪饮食在 Ripk3 敲除和野生型小鼠中诱导 DKD 模型。为了评估 DKD 中的线粒体功能障碍和白蛋白尿是否通过 Ripk3 依赖性途径发生,我们使用高糖处理的肾脏皮质单细胞 RNA 测序和过表达 RIPK3 的永生化足细胞进行了研究。
在白蛋白尿增多和足细胞数量减少的糖尿病肾小球中,RIPK3 在足细胞中的表达增加。与非糖尿病对照组(p=0.002)和非白蛋白尿性糖尿病患者(p=0.046)相比,白蛋白尿性糖尿病患者的血浆 RIPK3 水平显著升高。血浆 RIPK3 水平最高 tertile 的参与者发生肾脏进展的风险更高(风险比[HR] 2.29[1.05-4.98])和发生慢性肾脏病(HR 4.08[1.10-15.13])的风险更高。Ripk3 敲除可改善 DKD 小鼠的白蛋白尿、足细胞丢失和肾脏超微结构。Ripk3 敲除的 DKD 小鼠的足细胞中,线粒体片段化减少,磷酸甘油酸变位酶家族成员 5(PGAM5)和动力相关蛋白 1(Drp1)等与线粒体分裂相关的蛋白上调,以及线粒体 ROS 减少。在培养的足细胞中,RIPK3 抑制通过降低混合谱系激酶结构域样蛋白(MLKL)、PGAM5 和 p-Drp1 S616 以及 Drp1 的线粒体易位来减少线粒体分裂和线粒体功能障碍。
该研究表明,RIPK3 反映了 DKD 患者肾功能的恶化。此外,RIPK3 通过 MLKL 调节 PGAM5-Drp1 信号通路诱导糖尿病性足细胞病。抑制 RIPK3 可能是治疗 DKD 的一种有前途的治疗选择。